[What’s news in dermatological therapy?]

pubmed-ncbi-logos

Journal: Ann Dermatol Venereol 2013 Nov;140 Suppl 3:S293-302

Author(s): Guillot B

Innovations in dermatological therapy remain rare. In 2013, increase in the knowledge of mechanism of action and place in the therapeutic strategies concern some recent drugs. For psoriasis treatment, efficacy and safety of anti IL-17 and anti JAK pathway has been demonstrated in randomized studies versus placebo. In other inflammatory diseases, the role of rituximab in auto immune bullous diseases and of omalizumab in chronic urticaria is better known. This year was published the first randomized trial using anti TNF in hidradenitis suppurativa with positive but limited effects. For infectious diseases, the role of prolonged antibiotherapy in the management of recurrent cellulitis is well documented and new antibiotics appears for the treatment of multi resistant bacteria in infection of skin and soft tissues. Finaly, analysis of quality criteria in dermatological trial showed great capability for increase in quality, a strong prerequiste for treating our patient with safety and efficacy.

Dermatology Journal and/or Publisher

Journal Name: Annales de dermatologie et de vénéréologie
Journal Abbreviation: Ann Dermatol Venereol
Journal Volume: 140 Suppl 3, Issue:
Journal Date Published: 2013-11-01

National Center for Biotechnology Information

PMI ID: 24365501
Article: http://www.ncbi.nlm.nih.gov/pubmed/24365501
Created: 2013-12-24

Abstract Source: National Center for Biotechnology Information, U.S. National Library of Medicine Abstract Query for “Hidradenitis suppurativa”

Tags:

HSAWARENESS.ORG | Fighting for Hidradenitis suppurativa (HS), a.k.a Acne Inversa Patient and Doctor Awareness ©2017 hidradenitissuppurativaawareness.org  All Rights Reserved. Your use of this website constitutes explicit agreement to our Terms of Use and Privacy Policies. This website does not provide medical advice, diagnosis or treatment.

Translate »

Log in with your credentials

Forgot your details?